Skip to main content
. 2018 Feb 15;9(3):269. doi: 10.1038/s41419-018-0302-x

Fig. 3. EGF mainly acts through the EGFR-PI3K-PDK1 pathway to enhance the expression of YAP in HCC cells.

Fig. 3

a, b WB was used to detect the effect of EGF treatment for 4 h on the expression of YAP with the inhibitors of EGFR or its downsream members, including the EGFR inhibitor (10uM Gefitinib), PI3K inhibitor (10 uM LY294002, 5 uM Wortmannin), PDK1 inhibitor (10uM GSK2334470, 10 uM BX-795), pan-Akt inhibitor(10 uM MK-2206) and MEK inhibitor(10 uM Trametinib, 10 uM U0126) in the Si RhoA transfected HepG2 and SMMC7721 cells for 48 h in HepG2 and SMMC7721 cells. c, d CCK8 assays were used to detect the effect of YAP knockdown combined with 50 ng/ml EGF stimulation for 48 h on the proliferation of the two HCC cell lines. e, f WB was used to examine the effect of combined treatment on the core effectors of the EGFR downstream signaling. T-test was used to detect the difference. (*P < 0.05, **P < 0.01, ***P < 0.001)